Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06006247 · ClinicalTrials.gov registry record · Phase 2
Early Parkinson's Disease Monotherapy With CVN424
A Phase 2 study of Parkinson's Disease, sponsored by Cerevance Beta.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT06006247: Completed Phase 2 study of Parkinson's Disease, sponsored by Cerevance Beta.
NCT06006247 is a Phase 2 study of Parkinson's Disease that has completed, run by Cerevance Beta. The registered enrollment target is 64 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06006247, a Phase 2 study of Parkinson's Disease, has completed, sponsored by Cerevance Beta.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.
Primary Outcome
MDS-UPDRS was a comprehensive 50-question assessment designed to evaluate both motor and non-motor symptoms associated with PD. It included sections that were independently completed by individuals with PD and their caregivers, as well as sections that were consistently completed by the same approved rater throughout the study. Parts II and III were used in this study. Part II (13 items; range 0-52) assesses motor experiences of daily living and is completed by participants. Part III (33 scores
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CVN424 150 mg
Study Locations (20)
Florida
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- SFM Clinical Research, LLC - Boca Raton
- N1 Research LLC - Orlando
- Parkinson's Disease Treatment Center of SWFL - Port Charlotte
- University of South Florida Parkinson's Disease and Movement Disorders Center - Tampa
Arizona
- Barrow Neurological Institute - Phoenix
- St Joseph's Hospital and Medical Center - Phoenix
- Muhammad Ali Parkinson Center - Phoenix
- Movement Disorders Center of Arizona, LLC - Scottsdale
Michigan
- University of Michigan Hospital / Michigan Clinical Research Unit (MCRU) Cardiovascular Center - Ann Arbor
- University of Michigan Department of Neurology - Ann Arbor
- Quest Research Institute - Farmington Hills
Kentucky
- University of Kentucky, Dept of Neurology Kentucky Neuroscience Institute Research - Lexington
- University of Kentucky, Center for Clinical and Translational Sciences - Lexington
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Parkinson's Research Centers of America - Palo Alto - Palo Alto
Colorado
- CenExel Rocky Mountain Clinical Research - Englewood
Georgia
- Augusta University - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2025-02-13 |
| Phase | Phase 2 |
What the finished NCT06006247 record still lists
NCT06006247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06006247 names 20 study sites across 10 states, led by Florida, Arizona, Michigan.
Frequently Asked Questions
What is clinical trial NCT06006247 about?
NCT06006247 is a clinical study titled "Early Parkinson's Disease Monotherapy With CVN424". This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on mo...
What is the current status of trial NCT06006247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-09-11. Estimated completion is 2025-02-13.
What conditions does trial NCT06006247 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT06006247?
The interventions under investigation include: Placebo (DRUG), CVN424 150 mg (DRUG).
Who is sponsoring clinical trial NCT06006247?
This trial is sponsored by Cerevance Beta, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06006247 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06006247's enrollment target sits among peer trials
64 72nd of 158 higher than 86 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
Tenapanor in Synucleinopathy-Related Constipation
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI